beta-alanine has been researched along with MS (Multiple Sclerosis) in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Future treatments of multiple sclerosis (MS), a chronic autoimmune neurodegenerative disease of the central nervous system (CNS), aim for simultaneous early targeting of peripheral immune function and neuroinflammation." | 1.56 | Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis. ( Balletta, S; Bruno, A; Bullitta, S; Buttari, F; Caioli, S; Centonze, D; De Vito, F; Dolcetti, E; Fresegna, D; Gentile, A; Guadalupi, L; Mandolesi, G; Musella, A; Nencini, M; Rizzo, FR; Sanna, K; Stampanoni Bassi, M; Vanni, V; Vitiello, L, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Musella, A | 1 |
| Gentile, A | 1 |
| Guadalupi, L | 1 |
| Rizzo, FR | 1 |
| De Vito, F | 1 |
| Fresegna, D | 1 |
| Bruno, A | 1 |
| Dolcetti, E | 1 |
| Vanni, V | 1 |
| Vitiello, L | 1 |
| Bullitta, S | 1 |
| Sanna, K | 1 |
| Caioli, S | 1 |
| Balletta, S | 1 |
| Nencini, M | 1 |
| Buttari, F | 1 |
| Stampanoni Bassi, M | 1 |
| Centonze, D | 1 |
| Mandolesi, G | 1 |
| Moore, TJ | 1 |
| Furberg, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study[NCT05245344] | 154 participants (Anticipated) | Observational | 2022-04-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for beta-alanine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
Topics: Animals; Anti-Inflammatory Agents; beta-Alanine; Cell Line; Central Nervous System; Disease Models, | 2020 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clin | 2012 |